Paul's questions to Syndax Pharmaceuticals Inc (SNDX) leadership • Q2 2025
Question
Paul, on behalf of Michael Schmidt, asked for commentary on the overall survival (OS) improvement seen in the BEAT AML combo trial and whether further updates are planned. He also inquired about the key CR and MRD negativity benchmarks for the upcoming intensive chemotherapy combo data.
Answer
CMO Dr. Nick Botwood explained that for the BEAT AML study, the most important early measures were the high rates of complete remission (CR) and MRD negativity, noting that OS follow-up is still short. For the intensive chemo combo, he stated that MRD-negative CR is a key endpoint that could support accelerated approval, and data updates from two studies are expected later in the year.